[1]张睿,刘帅辉,于珮.痛风合并慢性肾脏疾病的药物治疗[J].国际内分泌代谢杂志,2016,36(02):82-88.[doi:10.3760/cma.j.issn.1673-4157.2016.02.003]
　Zhang Rui,Liu Shuaihui,Yu Pei..Drug therapy of gout combined with chronic kidney disease[J].International Journal of Endocrinology and Metabolism,2016,36(02):82-88.[doi:10.3760/cma.j.issn.1673-4157.2016.02.003]
点击复制

痛风合并慢性肾脏疾病的药物治疗()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
36
期数:
2016年02期
页码:
82-88
栏目:
高尿酸血症/痛风相关代谢性疾病专栏
出版日期:
2016-03-20

文章信息/Info

Title:
Drug therapy of gout combined with chronic kidney disease
作者:
张睿; 刘帅辉; 于珮
300070 天津医科大学代谢病医院肾透析科,天津医科大学代谢病医院内分泌研究所,卫生部激素与发育重点实验室, 天津市代谢性疾病重点实验室
Author(s):
Zhang Rui;  Liu Shuaihui;  Yu Pei.
Department of Kidney Dialysis, Key Laboratory of Hormones and Development(Ministry of Health),Tianjin Key Laboratory of Metabolic Diseases, Tianjin Metabolic Diseases Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin 3
关键词:
痛风;  高尿酸血症;  慢性肾脏疾病;  药物治疗
Keywords:
Gout;  Hyperuricemia;  Chronic kidney disease;  Drug therapy
DOI:
10.3760/cma.j.issn.1673-4157.2016.02.003
摘要:
慢性肾脏疾病(CKD)正困扰越来越多的痛风患者,是痛风最常见的合并症。然而,目前痛风和CKD的随机对照试验比较有限,并且指南并没有明确的痛风合并CKD患者的用药指导。痛风的治疗主要是控制痛风发作以及降尿酸治疗。非甾体类抗炎药物和秋水仙碱是急性痛风发作的一线治疗药物。然而,对于CKD患者,非甾体类抗炎药物因肾损伤并不被推荐。同样,秋水仙碱的毒性在CKD患者中是加剧的,其剂量应根据肾功能情况酌减。类固醇激素的使用也需要权衡利弊,因此免疫治疗可能成为未来治疗手段的重要方面。别嘌呤醇、非布司他、促尿酸排泄药物及聚乙二醇重组尿酸酶用于控制急性发作后的高尿酸血症。然而,因CKD患者需要限制别嘌呤醇剂量,从而影响了其疗效。聚乙二醇重组尿酸酶有待进一步研究,非布司他未曾在肌酐清除率<30 ml/min的患者中研究。
Abstract:
Chronic kidney disease(CKD)is the most common comorbidity of gout that increasingly plagues patients these years. However, data from randomized controlled trials in patients with gout and CKD are limited, and there is no explicit treatment guidance in guidelines for management of patients with gout and CKD. The goals of gout treatment are to control pain and lower the level of serum urate. Though nonsteroidal anti-inflammatory drugs(NSAIDs)and colchicine are used to treat acute gout flares as the fisrt line medications, NSAIDs are not recommended in patients with CKD for the kidney injury. Similarly, the toxicity of colchicine is increased in patients with CKD that means the dosage should be decreased moderately based on the level of kidney function. We should also weigh the advantages and disadvantages for steroid hormone therapy, which suggests changes in immunotherapy might be necessary. Allopurinol, febuxostat, uricosuric agents and pegloticase are all effective agents for the hyperuricemia secondary to acute gout flares. Nevertheless, in patients with CKD, the efficacy of allopurinol is unsatisfied due to its limited dosage, and the pegloticase requires further study, while little research has been done on febuxostat in patients with creatinine clearance rate less than 30 ml/min.

参考文献/References:

[1] Bieber JD, Terkeltaub RA. Gout: on the brink of novel therapeutic options for an ancient disease[J]. Arthritis Rheum,2004,50(8):2400-2414.
[2] Saag KG, Choi H. Epidemiology, risk factors, and lifestyle modifications for gout[J]. Arthritis Res Ther, 2006,(8 Suppl 1):S2.
[3] Wallace KL, Riedel AA, Joseph-Ridge N,et al. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population[J]. J Rheumatol,2004,31(8):1582-1587.
[4] Anker SD, Doehner W, Rauchhaus M,et al. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic taging[J]. Circulation,2003,107(15):1991-1997.
[5] Clive DM. Renal transplant-associated hyperuricemia and gout[J]. J Am Soc Nephrol, 2000,11(5):974-979.
[6] Lin HY, Rocher LL, McQuillan MA,et al. Cyclosporine-induced hyperuricemia and gout[J]. N Engl J Med,1989,321(5):287-292.
[7] Edvardsson VO, Kaiser BA, Polinsky MS,et al. Natural history and etiology of hyperuricemia following pediatric renal transplantation[J]. Pediatr Nephrol,1995,9(1):57-60.
[8] Umekawa T, Chegini N, Khan SR. Increased expression of monocyte chemoattractant protein-1(MCP-1)by renal epithelial cells in culture on exposure to calcium oxalate, phosphate and uric acid crystals[J]. Nephrol Dial Transplant,2003,18(4):664-669.
[9] Spencer HW, Yarger WE, Robinson RR. Alterations of renal function during dietary-induced hyperuricemia in the rat[J]. Kidney Int,1976,9(6):489-500.
[10] Iseki K, Ikemiya Y, Inoue T,et al. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort[J]. Am J Kidney Dis,2004,44(4):642-650.
[11] Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008[J]. Am J Med,2012,125(7):679-687.e1. DOI: 10.1016/j.amjmed.2011.09.033.
[12] Fels E, Sundy JS. Refractory gout: what is it and what to do about it?[J]. Curr Opin Rheumatol,2008,20(2):198-202. DOI: 10.1097/BOR.0b013e3282f4eff5.
[13] Petersel D, Schlesinger N. Treatment of acute gout in hospitalized patients[J]. J Rheumatol,2007,34(7):1566-1568.
[14] Singh JA, Hodges JS, Asch SM. Opportunities for improving medication use and monitoring in gout[J]. Ann Rheum Dis,2009,68(8):1265-1270. DOI: 10.1136/ard.2008.092619.
[15] Zhang W, Doherty M, Bardin T,et al. EULAR evidence based recommendations for gout. Part Ⅱ: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics(ESCISIT)[J]. Ann Rheum Dis,2006,65(10):1312-1324.
[16] National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification[J]. Am J Kidney Dis,2002,39(2 Suppl 1):S1-S266.
[17] Jordan KM, Cameron JS, Snaith M,et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout[J]. Rheumatology(Oxford),2007,46(8):1372-1374.
[18] Abdellatif AA, Elkhalili N. Management of gouty arthritis in patients with chronic kidney disease[J]. Am J Ther,2014,21(6):523-534. DOI: 10.1097/MJT.0b013e318250f83d.
[19] Levey AS, Coresh J, Balk E,et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification[J].Ann Intern Med,2003,139(2):137-147.
[20] Rider TG, Jordan KM. The modern management of gout[J].Rheumatology(Oxford),2010,49(1):5-14. DOI: 10.1093/rheumatology/kep306.
[21] Munar MY, Singh H. Drug dosing adjustments in patients with chronic kidney disease[J].Am Fam Physician,2007,75(10):1487-1496.
[22] Terkeltaub RA. Colchicine update: 2008[J].Semin Arthritis Rheum,2009,38(6):411-419. DOI: 10.1016/j.semarthrit.2008.08.006.
[23] Justiniano M, Dold S, Espinoza LR. Rapid onset of muscle weakness(rhabdomyolysis)associated with the combined use of simvastatin and colchicine[J].J Clin Rheumatol,2007,13(5):266-268.
[24] Wilbur K, Makowsky M. Colchicine myotoxicity: case reports and literature review[J]. Pharmacotherapy, 2004,24:1784-1792. DOI:10.1592/phco.24.17.1784.52334
[25] Dykeman-Sharpe J. Treatment of acute gouty arthritis in patients with chronic kidney disease[J].CANNT J,2004,14(1):48-50.
[26] Man CY, Cheung IT, Cameron PA,et al. Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute goutlike arthritis: a double-blind, randomized, controlled trial[J].Ann Emerg Med,2007,49(5):670-677.
[27] Richette P, Bardin T. Should prednisolone be first-line therapy for acute gout?[J]. Lancet,2008,372(9646):1301. DOI: 10.1016/S0140-6736(08)61548-2.
[28] El-Zawawy H, Mandell BF. Managing gout: how is it different in patients with chronic kidney disease?[J].Cleve Clin J Med,2010,77(12):919-928. DOI: 10.3949/ccjm.77a.09080.
[29] Clive DM. Renal transplant-associated hyperuricemia and gout[J].J Am Soc Nephrol,2000,11(5):974-979.
[30] Schwiebert LP. Joint pain. In: Mengel MB, Schwiebert LP,eds.Family Medicine: Ambulatory Care & Prevention. 4th ed.New York, NY: Lange Medical Books/McGraw-Hill; 2005:236-244.
[31] Schmidt M, Christiansen CF, Mehnert F,et al. Non-steroidal anti-inflammatory drug use and risk of atrial fibrillation or flutter: population based case-control study[J].BMJ,2011,343:d3450. DOI: 10.1136/bmj.d3450.
[32] Swarup A, Sachdeva N, Schumacher HR Jr. Dosing of antirheumatic drugs in renal disease and dialysis[J].J Clin Rheumatol,2004,10(4):190-204.
[33] Cohen SD, Kimmel PL, Neff R,et al. Association of incident gout and mortality in dialysis patients[J]. J Am Soc Nephrol,2008,19(11):2204-2210. DOI: 10.1681/ASN. 2007111256.
[34] Baroletti S, Bencivenga GA, Gabardi S. Treating gout in kidney transplant recipients[J].Prog Transplant,2004,14(2):143-147.
[35] Martinon F, Pétrilli V, Mayor A,et al. Gout-associated uric acid crystals activate the NALP3 inflammasome[J].Nature,2006,440(7081):237-241.
[36] So A, De Smedt T, Revaz S,et al. A pilot study of IL-1 inhibition by anakinra in acute gout[J].Arthritis Res Ther,2007,9(2):R28.
[37] So A, De Meulemeester M, Pikhlak A, et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase Ⅱ, dose-ranging study[J]. Arthritis Rheum, 2010, 62:3064-3076. DOI:10.1002/art.27600.
[38] Keenan RT, O'Brien WR, Lee KH,et al. Prevalence of contraindications and prescription of pharmacologic therapies for gout[J].Am J Med,2011,124(2):155-163. DOI: 10.1016/j.amjmed.2010.09.012.
[39] Chao J, Terkeltaub R.A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout[J]. Curr Rheumatol Rep, 2009,11(2):135-140.
[40] Tausche AK, Jansen TL, Schröder HE,et al. Gout-current diagnosis and treatment[J].Dtsch Arztebl Int,2009,106(34-35):549-555. DOI: 10.3238/arztebl.2009.0549.
[41] Mayer MD, Khosravan R, Vernillet L,et al. Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment[J].Am J Ther,2005,12(1):22-34.
[42] Perez-Ruiz F, Alonso-Ruiz A, Calabozo M,et al. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout[J].Ann Rheum Dis,1998,57(9):545-549.
[43] Fujimori S, Ooyama K, Ooyama H,et al. Efficacy of benzbromarone in hyperuricemic patients associated with chronic kidney disease[J]. Nucleosides Nucleotides Nucleic Acids,2011,30(12):1035-1038. DOI: 10.1080/15257770.2011.622732.
[44] Mazali FC, Johnson RJ, Mazzali M. Use of uric acid-lowering agents limits experimental cyclosporine nephropathy[J]. Nephron Exp Nephrol,2012,120(1):e12-e19.DOI:10.1159/000330274.

相似文献/References:

[1]李树颖,孙丽荣.膳食营养与高尿酸血症和痛风的关系[J].国际内分泌代谢杂志,2016,36(04):223.[doi:10.3760/cma.j.issn.1673-4157.2016.04.03]
　Li Shuying,Sun Lirong.Relationship between dietary nutrients and hyperuricemia and gout[J].International Journal of Endocrinology and Metabolism,2016,36(02):223.[doi:10.3760/cma.j.issn.1673-4157.2016.04.03]
[2]文钟,童晓霞,谢文光,等.三磷酸腺苷结合盒转运蛋白G2与痛风/高尿酸血症[J].国际内分泌代谢杂志,2017,37(06):422.
　Wen Zhong*,Tong Xiaoxia,Xie Wenguang,et al.ATP-binding cassette sub-family G member 2 and gout/hyperuricemia[J].International Journal of Endocrinology and Metabolism,2017,37(02):422.
[3]安秀敏 蔡婷婷 缪珩.2型糖尿病患者血尿酸与血栓弹力图的 相关性分析[J].国际内分泌代谢杂志,2018,38(04):217.[doi:10.3760/cma.j.issn.1673-4157.2018.04.001]
　An Xiumin,Cai Tingting,Miao Heng..Correlation between serum uric acid and thrombelastogram in patients with type 2 diabetes[J].International Journal of Endocrinology and Metabolism,2018,38(02):217.[doi:10.3760/cma.j.issn.1673-4157.2018.04.001]
[4]高忠爱 韩菲 袁欣欣 孙梦迪 李晓晨 刘然 姜文慧 张立弋 常宝成 杨菊红.2型糖尿病合并不同类型高尿酸血症的 临床特征及危险因素分析[J].国际内分泌代谢杂志,2018,38(02):73.[doi:10.3760/cma.j.issn.1673-4157.2018.02.001]
　Gao Zhongai,Han Fei,Yuan Xinxin,et al.Analysis of clinical characteristics and risk factors of different types of hyperuricemia in patients with type 2 diabetes[J].International Journal of Endocrinology and Metabolism,2018,38(02):73.[doi:10.3760/cma.j.issn.1673-4157.2018.02.001]
[5]孔晓艳 鲁一兵.SGLT2抑制剂对2型糖尿病患者血尿酸水平的影响[J].国际内分泌代谢杂志,2020,40(02):97.[doi:10.3760/cma.j.issn.1673-4157.2020.02.006]
　Kong Xiaoyan,Lu Yibing.Effect of SGLT2 inhibitors on serum uric acid level in patients with type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2020,40(02):97.[doi:10.3760/cma.j.issn.1673-4157.2020.02.006]
[6]王英楠,成志锋.ABCG2基因多态性与痛风[J].国际内分泌代谢杂志,2020,40(05):351.[doi:10.3760/cma.j.cn121383-20200216-02026]
　Wang Yingnan,Cheng Zhifeng.ABCG2 Gene polymorphism and gout Medical University, Harbin 150001, China[J].International Journal of Endocrinology and Metabolism,2020,40(02):351.[doi:10.3760/cma.j.cn121383-20200216-02026]

备注/Memo

备注/Memo:
基金项目:天津市科委科技支撑计划重点项目(13ZCZDSY01300); 天津市卫计委重点攻关项目(15KG101)
更新日期/Last Update: 2016-03-20